News Archive // Chi-Med
AIM: £39.14 (-0.36) | Nasdaq: $25.70 (+0.65)
News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1
2
found Documents:80
Presentations | 1 Jan 2015

2015 JP Morgan Healthcare Conference (San Francisco)
View Presentation (PDF)
Presentations | 23 Dec 2014

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)
View Publication (PDF)
Presentations | 14 Oct 2014

ACR/ARHP 2014: HM-0523 (HMPL-523), a novel Syk inhibitor, blocks glomerulonephritis and extends life spans in lupus prone MRL/lpr mice
Read more
View Poster (JPG)
Presentations | 1 Oct 2014

2014 R&D Briefing
PDF
Presentations | 22 Aug 2014

Discovery of [savolitinib] as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (Journal of Medicinal Chemistry 2014)
For detailed information, please visit: http://pubs.acs.org/doi/abs/10.1021/jm500510f  
Read more
Presentations | 1 Jul 2014

2014 Interim Results Presentation
View Presentation (PDF)
Presentations | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer
View Poster (JPG)
Presentations | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors
View Poster (JPG)
Presentations | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors
View Poster (JPG)
Presentations | 1 Apr 2014

AACR 2014: Targeting MET in preclinical models to support the clinical development of AZD6094/HMPL-504 (savolitinib) in NSCLC
View Poster (PDF)
Presentations | 1 Apr 2014

AACR 2014: Anti-tumour activity of Epitinib in patient derived esophagus cancer models
View Poster (PDF)
Presentations | 1 Apr 2014

AACR 2014: Discovery and Early Development of HMPL-504 (savolitinib)
View Poster (PDF)
Presentations | 1 Feb 2014

2013 Full Year Results Presentation
View Presentation (PDF)
Presentations | 15 Oct 2013

ACR 2013: HMPL-523, a novel Syk inhibitor, significantly ameliorates the severity of arthritis in rodents
View Poster (PNG)
Presentations | 1 Oct 2013

2013 R&D Briefing
View Presentation (PDF)
Presentations | 1 Jul 2013

2013 Interim Results Presentation
View Presentation (PDF)
Presentations | 6 Apr 2013

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors
View Poster (PNG)
Presentations | 6 Apr 2013

AACR 2013: Preclinical disposition and pharmacokinetics of savolitinib, a novel selective cMet inhibitor
View Poster (JPG)
Presentations | 6 Apr 2013

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification
View Poster (JPG)
Presentations | 6 Apr 2013

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer
View Poster (JPG)
Presentations | 1 Mar 2013

2012 Full Year Results Presentation
View Presentation (PDF)
Presentations | 21 Dec 2012

HMPL-004 (Andrographis paniculata extract) Prevents Development of Murine Colitis by Inhibiting T-cell Proliferation and TH1/TH17 Responses (Inflammatory Bowel Diseases 2013)
View Publication (PDF)
Presentations | 28 Nov 2012

Chi-Med/Nestlé Health Science Analyst Conference Call Transcript
Download Transcript (PDF)
Presentations | 14 Oct 2012

ISSX 2012: Pharmacokinetic/Pharmacodynamic Modeling of Epitinib to Evaluate the Anti-cancer Effect on A431 Tumor Xenograft in Nude Mice
View Poster (JPG)
Presentations | 9 Oct 2012

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis (American Journal of Gastroenterology 2013)
View Publication (PDF)
Presentations | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors
View Poster (JPG)
Presentations | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors
View Poster (JPG)
Presentations | 6 Apr 2011

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models
View Poster (PDF)
Presentations | 30 Nov 2010

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)
View Publication (PDF)
Presentations | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor
View Poster (JPG)
1
2